gretel
01 Dec 2017
More coverage of "vital" test Nice PR from the Burnet Institute - very long piece about this "vital" new test:[link] Extracts: "Vital HIV test now a reality Tracy Parish 01 December, 2017 On World AIDS Day 2017, Omega Diagnostics, the medical diagnostics company focused on allergy, food intolerance and infectious disease, has announced with Burnet Institute the commercial release of its VISITECT® CD4 point-of-care test. The CE-Marking follows successful performance evaluations of the test in India and the UK.... ....VISITECT® CD4, co-developed with the Burnet Institute, is the world’s first instrument-free and affordable rapid test for determining CD4 threshold in people living with HIV. It is designed for use at the point-of-care and provides a means for decentralisation of CD4 testing capacity to where it is most needed.... ....“We expect that the VISITECT® CD4 test will make a real difference in HIV treatment and prevention programs that care for many millions of patients worldwide, which is exactly what we set out to achieve.”
Maverick
01 Dec 2017
Been watching and reading.. Have just purchased with the imminent results in mind.Added to my only other Pharma stock VAL.Maverick
Disorder
01 Dec 2017
Re: Sells Stock is very limited in supply.Certainly no large sells of note.The small sells that hit the market are I suspect small holders who have held for a few years and suddenly see its passed break even for them.A little like PYC etc... Some people assign stock to bottom drawer if it doesn't double in a week... lol... and then just sell when a point is met.The fantastic news we got this week about the CE approval provided better liquidity and allowed a better sell/buy market for the day..Yesterday we are back to market has no stock.Today that is even more evident even though the trade volumes are small.We have results in 2 weeks...... They are going to show even more gains and improvement on sales and revenues.It is IMO the beginning of a sustained rise. and as the CE approval becomes world wide known to have an Aids test like this how long before a bigger fish comes along to swallow up the IP??
Carefully Does It
30 Nov 2017
Sells I can't see any reason for reasonable volumes of shares to be available on the sell side at much below mid 20's, but it has been. Why sell?
Disorder
30 Nov 2017
Re: Good press coverage I wonder whether ODX may take the opportunity to provide a generic statement regards the test and CE approval on World Aids Day?Yesterday liquidity provided an opportunity for some stock to change hands.It looks like that is all done now and we are back to zero stock being available.
gretel
30 Nov 2017
Good press coverage Good coverage in the Herald:[link] I though this extract in the Times was noteworthy:[link] Omega confirmed that the CE Mark, a certification of quality, was in place after trials in India and Britain had shown that the kit was performing robustly. As a result it is available for sale to businesses in countries not requiring any additional product registration.The company is now seeking approval through the World Health Organisation, which would allow the test to be made available through public sector procurement.Finncap, the broker, estimates that annual revenue of up to £10 million could be achieved from the manufacturing capacity at Omega’s sites in Scotland and India."
Disorder
30 Nov 2017
Ahead of World Aids Day. World Aids Day Tomorrow, and ODX have managed to secure the CE approval for their Aids test announced 2 days before.[link]
Disorder
29 Nov 2017
finnCap @ 30p Research analysts at finnCap have GBX 30.00 PT on Omega Diagnostics Group PLC (LON:ODX). finnCap’s PT means a potential upside of 42.86% from the company’s last close price. The rating was revealed in an analyst report on Wednesday, 29 November.
mnbvvvvvvvvvvvcxz
29 Nov 2017
Re: long overdue I tend to agree with your observations. However I think your target price somewhat too high.1. Not many closely follow individual shares relying on witchcraft like charts others look at fundamentals ratios betas etc. This share needs to be looked at from its medical perspective i.e. what the products can do for people which requires a little knowledge of science, medicine and in this case epidemiology. 2. Looking at the fundamentals and using parameters for values of similar businesses I value the shares somewhat lower than you 50-60p. They CD4 sales when they come in bulk will be on contracted tenders to international bodies like the WHO the Gates foundation and Governments like the Republic of South Africa so there will not be super profits to be had.3. To achieve the levels you aspire to would require a bid from a major Health Care business who understand the potential and have synergies with their existing product portfolios.4. The IDS situation is curious the allergy business would have been worth as much or more than the capitalisation of the company. IDS had £30 million in cash to spend but instead a very protracted period of negotiation still ongoing.No doubt some news release can be expected on the allergens which have better short term prospects in my opinion.
Disorder
29 Nov 2017
Re: long overdue Very nicely put mnbvvvvvvvvvvvcxz,Quite often especially when dealing with exploration stocks such as Oil, Gold etc, the word "Transformational" is used.Along with ODX current armoury of tests, todays announcement sets ODX firmly on the "Transformational" route.When I look at the "Total trades" today and the limited bias towards buys, its pretty easy IMO to see that people are not getting just what the news means.IMO this should be much nearer to 50p than to 20p and with results due in 2 weeks time, another repeat of last years growth figures should be propelling it to nearer 80p - £1.00p (From 50p)Instead we languish at this pitiful level....Only 10% above the recent oversubscribed placement level....
mnbvvvvvvvvvvvcxz
29 Nov 2017
long overdue The ISO 13485 Certification has been a long time coming. Now the next hurdle is the WHO approval for resource poor countries.Sales can take place in middle income countries who shadow the European Medical Device Directives. One such country is South Africa where 1 in 8 is HIV positive.According to a 2015 UNAIDS report there are 7 million people living with HIV in the country.If only 10% are CD4 tested annually that's 700,000 tests at a price of $5 makes $3,500,000 that's the potential on these conservative estimates. The GDP per capita is $11,000 approx. So the cost of the tests is not stratospheric.These prospects should be transformational.
Disorder
29 Nov 2017
Ready For Leg Up. Market is stuffed for access to shares.AIDS,Malaria,These were the two news items anticipated to propel ODX northwards prior to results.We now have the CE approval 2 days before World Aids Day.And the company are working on further tests..We know Malaria tests are anticipated to boom in sales during 2018, we know this because ODX told us so.The sp IMO no way reflects a fair value.It is in my opinion crazy season, just as it is with a few other stocks.Trade volumes have picked up slightly today (To be expected) but really? Total 400k traded... So far under everyone's radar its akin to a snakes belly on the ground.
Disorder
29 Nov 2017
Changed. So much has changed this year.Last set of results gave us a great insight with turnover and revenues up all by over 10%Then during the year a successful over subscribed placing at 18p.Today the news ODX holders have been anticipatiing and hoping for, was delivered 2 days ahead of World Aids Day...!!!!To receive news on VISITECT® Malaria really would be the icing on the cake...However, in true form, the share price doesn't reflect the progress made.Results should put a very firm line under "UNDERVALUED"
Disorder
29 Nov 2017
Re: Good news re CD4 this morning People should be buying this up to a £1.And with such a tightly held stock with such limited free shares it not outside the realms of possibility.Results in 2 weeks..... 
Omega Diagnostics GpVISITECT® CD4 CE-MarkRNS Number : 7714XOmega Diagnostics Group PLC29 November 2017 Omega Diagnostics Group PLC("Omega" or the "Company"
VISITECT® CD4 CE-Mark Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT® CD4 test for helping to manage people living with HIV, following successful performance evaluations in India and the UK. The successful completion of the CE-Mark process means these tests, which indicate whether a person's CD4 count is higher or lower than 350 cells/mm³, are available for general sale through business to business channels in countries not requiring individual product registration. The technical file forms the basis of the additional regulatory approval the Company will seek through the World Health Organisation Prequalification programme which assesses in vitro diagnostics tests for priority diseases and their suitability for use in resource-limited settings. A successful completion of this process will enable Omega to become eligible for public sector procurement. The Company anticipates that this process is likely to be completed during the second half of the next financial year. In addition, the Company is looking to expand its VISITECT® product portfolio and is working on an additional version of the VISITECT® CD4 test which utilises a 200 cells/ mm³ cut-off. Recent global health guidelines confirm an opportunity also exists for a test that can indicate advanced HIV disease (a CD4 cell count which is lower than 200 cells/mm³ and the Company is working to ensure it has a product portfolio encompassing both existing and new opportunities. Andrew Shepherd, Chief Executive Officer of Omega, commented: "We are pleased to have achieved this major milestone and whilst the early opportunities are likely to lead to modest sales during the next twelve months, we anticipate generating significant demand once we have completed all the regulatory hurdles. We look forward to providing the global health community with unique point-of-care tests which address a significant unmet need."
gretel
29 Nov 2017
Good news re CD4 this morning [link] (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT® CD4 test for helping to manage people living with HIV, following successful performance evaluations in India and the UK."I like the phrase "significant unmet need", which indicates substantial revenues for this still micro-cap company from around a year's time.And per today's news there's another test in the pipeline too.....
